title: Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.
authors.forename: Tommaso
authors.initials: T
authors.lastname: De Pas
authors.forename: Gianluca
authors.initials: G
authors.lastname: Spitaleri
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pelosi
authors.forename: Luciano
authors.initials: L
authors.lastname: De Carlis
authors.forename: Katia
authors.initials: K
authors.lastname: Lorizzo
authors.forename: Marzia
authors.initials: M
authors.lastname: Locatelli
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Curigliano
authors.forename: Francesca
authors.initials: F
authors.lastname: Toffalorio
authors.forename: Chiara
authors.initials: C
authors.lastname: Catania
authors.forename: Filippo
authors.initials: F
authors.lastname: de Braud
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016572:Cyclosporine / Q000008:administration & dosage*; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D016031:Liver Transplantation; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D011799:Quinazolines / Q000008:administration & dosage
chemical_list: D011799:Quinazolines; D016572:Cyclosporine; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors